Evaluation of the Novel PET Tracer [C]HACH242 for Imaging the GluN2B NMDA Receptor in Non-Human Primates.
1 August 2019. doid: 10.1007/s11307-018-1284-x
van der Aart J, Yaqub M, Kooijman EJM, Bakker J, Langermans JAM, Schuit RC, Hofman MBM, Christiaans JAM, Lammertsma AA, Windhorst AD, van Berckel BNM
View publicationThere are currently no positron emission tomography (PET) radiotracers for the GluN2B (NR2B) binding sites of brain N-methyl-D-aspartate (NMDA) receptors. In rats, the GluN2B antagonist Ro25-6981 reduced the binding of N-((5-(4-fluoro-2-[C]methoxyphenyl)pyridin-3-yl)methyl)cyclopentanamin ([C]HACH242). This paper reports the evaluation of [C]HACH242 PET in non-human primates at baseline and following administration of the GluN2B negative allosteric modulator radiprodil.
Advancing the boundaries of clinical drug development
Wondering how we can help you? Reach out to us.
